18 results on '"Jacquelot, Nicolas"'
Search Results
2. Innate Lymphoid Cells: Role in Immune Regulation and Cancer.
- Author
-
Chung, Douglas C., Jacquelot, Nicolas, Ghaedi, Maryam, Warner, Kathrin, and Ohashi, Pamela S.
- Subjects
- *
OVARIAN tumors , *KILLER cells , *IMMUNOSUPPRESSION , *IMMUNITY ,TUMOR prevention - Abstract
Simple Summary: Innate lymphoid cells (ILCs) are an emerging family of effector cells known to play a major role in innate defenses against pathogens, lymphoid organogenesis, tissue repair, and homeostasis. They are positioned strategically within tissues to provide the first line of defence and shape the ensuing adaptive immune cell response. Recent evidence suggests that ILCs contribute to immune regulation in different diseases, including cancer, and can have significant impact on disease outcome. In this review, we highlight the immunosuppressive roles of ILCs in cancer that inhibit effective immune surveillance and anti-tumour response. Immune regulation is composed of a complex network of cellular and molecular pathways that regulate the immune system and prevent tissue damage. It is increasingly clear that innate lymphoid cells (ILCs) are also armed with immunosuppressive capacities similar to well-known immune regulatory cells (i.e., regulatory T cells). In cancer, immunoregulatory ILCs have been shown to inhibit anti-tumour immune response through various mechanisms including: (a) direct suppression of anti-tumour T cells or NK cells, (b) inhibiting T-cell priming, and (c) promoting other immunoregulatory cells. To provide a framework of understanding the role of immunosuppressive ILCs in the context of cancer, we first outline a brief history and challenges related to defining immunosuppressive ILCs. Furthermore, we focus on the mechanisms of ILCs in suppressing anti-tumour immunity and consequentially promoting tumour progression. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. Type 2 innate lymphoid cells: a novel actor in anti-melanoma immunity.
- Author
-
Jacquelot, Nicolas and Belz, Gabrielle T.
- Subjects
- *
MELANOMA , *INNATE lymphoid cells , *MACROPHAGE colony-stimulating factor , *IMMUNE response , *IMMUNITY , *NATURAL immunity - Abstract
Immunity to melanoma is thought to be mainly mediated by adaptive immune cells. To what extent innate immunity, particularly innate lymphoid cells, drive the immune response and impact melanoma prognosis and therapeutic responsiveness is not well understood. In a recent article published in Nature Immunology, we uncovered a critical role that ILC2 play in the control of melanoma. Using both complementary mouse models and human samples, we showed that ILC2-derived granulocyte macrophage-colony stimulating factor (GM-CSF) drives eosinophil tumor recruitment and activation. We found that ILC2 express PD-1 which inhibits ILC2 effector function and impairs anti-tumor responses. We further demonstrated that the combination of IL-33 and anti-PD-1 blocking antibodies improved anti-tumor responses through the expansion of splenic and tumor-infiltrating ILC2 and eosinophils. These findings have revealed an essential mechanism involving ILC2 and eosinophils necessary for anti-melanoma immunity and immunotherapy responses. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Deconstructing deployment of the innate immune lymphocyte army for barrier homeostasis and protection.
- Author
-
Almeida, Francisca F., Jacquelot, Nicolas, and Belz, Gabrielle T.
- Subjects
- *
INNATE lymphoid cells , *LYMPHOCYTES , *HOMEOSTASIS , *HOSTS (Biology) , *DENDRITIC cells , *PHYSIOLOGY - Abstract
Summary: The study of the immune system has shifted from a purely dichotomous separation between the innate and adaptive arms to one that is now highly complex and reshaping our ideas of how steady‐state health is assured. It is now clear that immune cells do not neatly fit into these two streams and immune homeostasis depends on continual dialogue between multiple lineages of the innate (including dendritic cells, innate lymphoid cells, and unconventional lymphocytes) and adaptive (T and B lymphocytes) arms together with a finely tuned synergy between the host and microbes which is essential to ensure immune homeostasis. Innate lymphoid cells are critical players in this new landscape. Here, we discuss recent studies that have elucidated in detail the development of ILCs from their earliest progenitors and examine factors that influence their identification and ability to drive immune homeostasis and long‐term immune protection. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
5. Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma.
- Author
-
Jacquelot, Nicolas, Enot, David P., Flament, Caroline, Vimond, Nadège, Blattner, Carolin, Pitt, Jonathan M., Takahiro Yamazaki, Roberti, María Paula, Daillère, Romain, Vétizou, Marie, Poirier-Colame, Vichnou, Semeraro, Michaëla, Caignard, Anne, Slingluff Jr., Craig L., Sallusto, Federica, Rusakiewicz, Sylvie, Weide, Benjamin, Marabelle, Aurélien, Kohrt, Holbrook, and Dalle, Stéphane
- Subjects
- *
MELANOMA prognosis , *CHEMOKINE receptors , *T cells , *LYMPH node cancer , *PROTEIN expression , *PHYSIOLOGY , *ANIMAL experimentation , *ANIMALS , *ANTINEOPLASTIC agents , *CELL lines , *CELL receptors , *LUNG tumors , *MELANOMA , *METASTASIS , *MICE , *MONOCLONAL antibodies , *RESEARCH funding , *SKIN tumors , *PROPORTIONAL hazards models , *CASE-control method , *RECEIVER operating characteristic curves , *KAPLAN-Meier estimator , *PHARMACODYNAMICS - Abstract
Melanoma prognosis is dictated by tumor-infiltrating lymphocytes, the migratory and functional behavior of which is guided by chemokine or cytokine gradients. Here, we retrospectively analyzed the expression patterns of 9 homing receptors (CCR/CXCR) in naive and memory CD4+ and CD8+ T lymphocytes in 57 patients with metastatic melanoma (MMel) with various sites of metastases to evaluate whether T cell CCR/CXCR expression correlates with intratumoral accumulation, metastatic progression, and/or overall survival (OS). Homing receptor expression on lymphocytes strongly correlated with MMel dissemination. Loss of CCR6 or CXCR3, but not cutaneous lymphocyte antigen (CLA), on circulating T cell subsets was associated with skin or lymph node metastases, loss of CXCR4, CXCR5, and CCR9 corresponded with lung involvement, and a rise in CCR10 or CD103 was associated with widespread dissemination. High frequencies of CD8+CCR9+ naive T cells correlated with prolonged OS, while neutralizing the CCR9/CCL25 axis in mice stimulated tumor progression. The expansion of CLA-expressing effector memory CD8+ T cells in response to a single administration of CTLA4 blockade predicted disease control at 3 months in 47 patients with MMel. Thus, specific CCR/CXCR expression patterns on circulating T lymphocytes may guide potential diagnostic and therapeutic approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
6. Immune Checkpoints and Innate Lymphoid Cells—New Avenues for Cancer Immunotherapy.
- Author
-
Jacquelot, Nicolas, Ghaedi, Maryam, Warner, Kathrin, Chung, Douglas C., Crome, Sarah Q., and Ohashi, Pamela S.
- Subjects
- *
TUMOR treatment , *HOMEOSTASIS , *IMMUNE checkpoint inhibitors , *IMMUNE system , *KILLER cells , *LYMPHOCYTES , *CELL motility , *IMMUNOTHERAPY - Abstract
Simple Summary: Targeting the inhibitory receptors expressed by immune cells has revolutionized the clinical management of cancer patients. Initially developed to enhance T cell responses, recent investigations have demonstrated that innate lymphoid cells (ILC) also express many of these checkpoint molecules and could therefore be impacted by checkpoint blockade-based therapies. The diversity of the innate lymphoid cell family and their critical role in maintaining tissue homeostasis has drawn broad interest from the field to investigate their function in cancer. Here, we discuss recent findings highlighting the diversity of ILC in tissues and their capacity to migrate into organs upon inflammatory challenge. We further provide a comprehensive overview of the current knowledge on immune checkpoint (IC) expression on ILC, focusing on their therapeutic potential and capacity to modulate anti-tumor immune response. Immune checkpoints (IC) are broadly characterized as inhibitory pathways that tightly regulate the activation of the immune system. These molecular "brakes" are centrally involved in the maintenance of immune self-tolerance and represent a key mechanism in avoiding autoimmunity and tissue destruction. Antibody-based therapies target these inhibitory molecules on T cells to improve their cytotoxic function, with unprecedented clinical efficacies for a number of malignancies. Many of these ICs are also expressed on innate lymphoid cells (ILC), drawing interest from the field to understand their function, impact for anti-tumor immunity and potential for immunotherapy. In this review, we highlight ILC specificities at different tissue sites and their migration potential upon inflammatory challenge. We further summarize the current understanding of IC molecules on ILC and discuss potential strategies for ILC modulation as part of a greater anti-cancer armamentarium. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. Natural Killer Cells and Type 1 Innate Lymphoid Cells in Hepatocellular Carcinoma: Current Knowledge and Future Perspectives.
- Author
-
Jacquelot, Nicolas, Seillet, Cyril, Souza-Fonseca-Guimaraes, Fernando, Sacher, Adrian G., Belz, Gabrielle T., and Ohashi, Pamela S.
- Subjects
- *
INNATE lymphoid cells , *HEPATOCELLULAR carcinoma , *LABORATORY mice , *LIVER cells , *LIVER cancer , *KILLER cells - Abstract
Natural killer (NK) cells and type 1 innate lymphoid cells (ILC1) are specific innate lymphoid cell subsets that are key for the detection and elimination of pathogens and cancer cells. In liver, while they share a number of characteristics, they differ in many features. These include their developmental pathways, tissue distribution, phenotype and functions. NK cells and ILC1 contribute to organ homeostasis through the production of key cytokines and chemokines and the elimination of potential harmful bacteria and viruses. In addition, they are equipped with a wide range of receptors, allowing them to detect "stressed cells' such as cancer cells. Our understanding of the role of innate lymphoid cells in hepatocellular carcinoma (HCC) is growing owing to the development of mouse models, the progress in immunotherapeutic treatment and the recent use of scRNA sequencing analyses. In this review, we summarize the current understanding of NK cells and ILC1 in hepatocellular carcinoma and discuss future strategies to take advantage of these innate immune cells in anti-tumor immunity. Immunotherapies hold great promise in HCC, and a better understanding of the role and function of NK cells and ILC1 in liver cancer could pave the way for new NK cell and/or ILC1-targeted treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. Type 2 Innate Lymphoid Cells Protect against Colorectal Cancer Progression and Predict Improved Patient Survival.
- Author
-
Huang, Qiutong, Jacquelot, Nicolas, Preaudet, Adele, Hediyeh-zadeh, Soroor, Souza-Fonseca-Guimaraes, Fernando, McKenzie, Andrew N. J., Hansbro, Philip M., Davis, Melissa J., Mielke, Lisa A., Putoczki, Tracy L., Belz, Gabrielle T., and Moretta, Lorenzo
- Subjects
- *
CARCINOGENESIS , *ANIMAL experimentation , *BIOLOGICAL models , *COLON tumors , *IMMUNITY , *INFLAMMATION , *LYMPHOCYTES , *MACHINE learning , *MICE , *SURVIVAL , *DISEASE progression ,RECTUM tumors - Abstract
Simple Summary: Colorectal cancer is the second leading cause of cancer-related death worldwide. The immune system plays a key role in controlling tumour onset and development. However, our immune system is complex and includes many different cell types which differently impact colorectal cancer outcomes. In this study, we investigated the function of the specialised type 2 innate lymphoid cells (ILC2) in colorectal cancer development and progression. We found that ILC2 infiltrate colorectal tumours and their presence was associated with reduced tumour burden in mice. In patients, this infiltration correlated with improved overall survival. Collectively, our work reveals that ILC2s are beneficial to colorectal cancer outcomes. Chronic inflammation of the gastrointestinal (GI) tract contributes to colorectal cancer (CRC) progression. While the role of adaptive T cells in CRC is now well established, the role of innate immune cells, specifically innate lymphoid cells (ILCs), is not well understood. To define the role of ILCs in CRC we employed complementary heterotopic and chemically-induced CRC mouse models. We discovered that ILCs were abundant in CRC tumours and contributed to anti-tumour immunity. We focused on ILC2 and showed that ILC2-deficient mice developed a higher tumour burden compared with littermate wild-type controls. We generated an ILC2 gene signature and using machine learning models revealed that CRC patients with a high intratumor ILC2 gene signature had a favourable clinical prognosis. Collectively, our results highlight a critical role for ILC2 in CRC, suggesting a potential new avenue to improve clinical outcomes through ILC2-agonist based therapeutic approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma.
- Author
-
Jacquelot, Nicolas, Pitt, Jonathan M., Enot, David P., Roberti, Maria Paula, Duong, Connie P. M., Rusakiewicz, Sylvie, Eggermont, Alexander M., and Zitvogel, Laurence
- Subjects
- *
BIOMARKERS , *MELANOMA prognosis , *ADJUVANT treatment of cancer - Abstract
Existing clinical, anatomopathological and molecular biomarkers fail to reliably predict the prognosis of cutaneous melanoma. Biomarkers for determining which patients receive adjuvant therapies are needed. The emergence of new technologies and the discovery of new immune populations with different prognostic values allow the immune network in the tumor to be better understood. Importantly, new molecules identified and expressed by immune cells have been shown to reduce the antitumor immune efficacy of therapies, prompting researchers to develop antibodies targeting these so-called “immune checkpoints”, which have now entered the oncotherapeutic armamentarium. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
10. Targeting Potential of Innate Lymphoid Cells in Melanoma and Other Cancers.
- Author
-
Seo, Hobin, Verma, Amisha, Kinzel, Megan, Huang, Qiutong, Mahoney, Douglas J., and Jacquelot, Nicolas
- Subjects
- *
INNATE lymphoid cells , *TUMOR-infiltrating immune cells , *PROGRAMMED cell death 1 receptors , *IMMUNE response , *IMMUNE checkpoint proteins , *T cells - Abstract
Reinvigorating the killing function of tumor-infiltrating immune cells through the targeting of regulatory molecules expressed on lymphocytes has markedly improved the prognosis of cancer patients, particularly in melanoma. While initially thought to solely strengthen adaptive T lymphocyte anti-tumor activity, recent investigations suggest that other immune cell subsets, particularly tissue-resident innate lymphoid cells (ILCs), may benefit from immunotherapy treatment. Here, we describe the recent findings showing immune checkpoint expression on tissue-resident and tumor-infiltrating ILCs and how their effector function is modulated by checkpoint blockade-based therapies in cancer. We discuss the therapeutic potential of ILCs beyond the classical PD-1 and CTLA-4 regulatory molecules, exploring other possibilities to manipulate ILC effector function to further impede tumor growth and quench disease progression. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1.
- Author
-
Shin Foong Ngiow, Young, Arabella, Jacquelot, Nicolas, Takahiro Yamazaki, Enot, David, Zitvogel, Laurence, and Smyth, Mark J.
- Subjects
- *
T cells , *CD8 antigen , *TUMORS , *CANCER cells , *CANCER research - Abstract
Despite successes, thus far, a significant proportion of the patients treated with anti-PD1 antibodies have failed to respond. We use mouse tumor models of anti-PD1 sensitivity and resistance and flow cytometry to assess tumor-infiltrating immune cells immediately after therapy. We demonstrate that the expression levels of T-cell PD1 (PD1lo), myeloid, and T-cell PDL1 (PDL1hi) in the tumor microenvironment inversely correlate and dictate the efficacy of anti-PD1 mAb and function of intratumor CD8+ T cells. In sensitive tumors, we reveal a threshold for PD1 downregulation on tumor-infiltrating CD8+ T cells below which the release of adaptive immune resistance is achieved. In contrast, PD1hi T cells in resistant tumors fail to be rescued by anti-PD1 therapy and remain dysfunctional unless intratumor PDL1lo immune cells are targeted. Intratumor Tregs are partly responsible for the development of anti-PD1--resistant tumors and PD1hi CD8+ T cells. Our analyses provide a framework to interrogate intratumor CD8+ T-cell PD1 and immune PDL1 levels and response in human cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
12. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors.
- Author
-
Routy, Bertrand, Le Chatelier, Emmanuelle, Derosa, Lisa, Duong, Connie P. M., Tidjani Alou, Maryam, Daillère, Romain, Fluckiger, Aurélie, Messaoudene, Meriem, Rauber, Conrad, Roberti, Maria P., Fidelle, Marine, Flament, Caroline, Poirier-Colame, Vichnou, Opolon, Paule, Klein, Christophe, Iribarren, Kristina, Mondragón, Laura, Jacquelot, Nicolas, Qu, Bo, and Ferrere, Gladys
- Subjects
- *
CANCER patients , *GUT microbiome , *ANTIBIOTICS , *FECAL microbiota transplantation , *AKKERMANSIA muciniphila - Abstract
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis induce sustained clinical responses in a sizable minority of cancer patients.We found that primary resistance to ICIs can be attributed to abnormal gut microbiome composition. Antibiotics inhibited the clinical benefit of ICIs in patients with advanced cancer. Fecal microbiota transplantation (FMT) from cancer patients who responded to ICIs into germ-free or antibiotic-treated mice ameliorated the antitumor effects of PD-1 blockade, whereas FMT from nonresponding patients failed to do so. Metagenomics of patient stool samples at diagnosis revealed correlations between clinical responses to ICIs and the relative abundance of Akkermansia muciniphila. Oral supplementation with A. muciniphila after FMTwith nonresponder feces restored the efficacy of PD-1 blockade in an interleukin-12– dependent manner by increasing the recruitment of CCR9+CXCR3+CD4+ T lymphocytes into mouse tumor beds. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
13. Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects.
- Author
-
Daillère, Romain, Vétizou, Marie, Waldschmitt, Nadine, Yamazaki, Takahiro, Isnard, Christophe, Poirier-Colame, Vichnou, Duong, Connie P.M., Flament, Caroline, Lepage, Patricia, Roberti, Maria Paula, Routy, Bertrand, Jacquelot, Nicolas, Apetoh, Lionel, Becharef, Sonia, Rusakiewicz, Sylvie, Langella, Philippe, Sokol, Harry, Kroemer, Guido, Enot, David, and Roux, Antoine
- Subjects
- *
ENTEROCOCCUS hirae , *CYCLOPHOSPHAMIDE , *ANTINEOPLASTIC agents , *IMMUNOMODULATORS , *PHARMACODYNAMICS , *DRUG efficacy - Abstract
Summary The efficacy of the anti-cancer immunomodulatory agent cyclophosphamide (CTX) relies on intestinal bacteria. How and which relevant bacterial species are involved in tumor immunosurveillance, and their mechanism of action are unclear. Here, we identified two bacterial species, Enterococcus hirae and Barnesiella intestinihominis that are involved during CTX therapy. Whereas E. hirae translocated from the small intestine to secondary lymphoid organs and increased the intratumoral CD8/Treg ratio, B. intestinihominis accumulated in the colon and promoted the infiltration of IFN-γ-producing γδT cells in cancer lesions. The immune sensor, NOD2, limited CTX-induced cancer immunosurveillance and the bioactivity of these microbes. Finally, E. hirae and B. intestinihominis specific-memory Th1 cell immune responses selectively predicted longer progression-free survival in advanced lung and ovarian cancer patients treated with chemo-immunotherapy. Altogether, E. hirae and B. intestinihominis represent valuable “oncomicrobiotics” ameliorating the efficacy of the most common alkylating immunomodulatory compound. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
14. Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance.
- Author
-
Pietrocola, Federico, Pol, Jonathan, Vacchelli, Erika, Rao, Shuan, Enot, David P., Baracco, Elisa E., Levesque, Sarah, Castoldi, Francesca, Jacquelot, Nicolas, Yamazaki, Takahiro, Senovilla, Laura, Marino, Guillermo, Aranda, Fernando, Durand, Sylvère, Sica, Valentina, Chery, Alexis, Lachkar, Sylvie, Sigl, Verena, Bloy, Norma, and Buque, Aitziber
- Subjects
- *
LOW-calorie diet , *ANTINEOPLASTIC agents , *AUTOPHAGY , *T cells , *HYDROXYCITRIC acid , *SPERMIDINE - Abstract
Summary Caloric restriction mimetics (CRMs) mimic the biochemical effects of nutrient deprivation by reducing lysine acetylation of cellular proteins, thus triggering autophagy. Treatment with the CRM hydroxycitrate, an inhibitor of ATP citrate lyase, induced the depletion of regulatory T cells (which dampen anticancer immunity) from autophagy-competent, but not autophagy-deficient, mutant KRAS-induced lung cancers in mice, thereby improving anticancer immunosurveillance and reducing tumor mass. Short-term fasting or treatment with several chemically unrelated autophagy-inducing CRMs, including hydroxycitrate and spermidine, improved the inhibition of tumor growth by chemotherapy in vivo. This effect was only observed for autophagy-competent tumors, depended on the presence of T lymphocytes, and was accompanied by the depletion of regulatory T cells from the tumor bed. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
15. Regulation of CD4+NKG2D+ Th1 Cells in Patients with Metastatic Melanoma Treated with Sorafenib: Role of IL-15Rα and NKG2D Triggering.
- Author
-
Romero, Ana I., Chaput, Nathalie, Poirier-Colame, Vichnou, Rusakiewicz, Sylvie, Jacquelot, Nicolas, Chaba, Kariman, Mortier, Erwan, Jacques, Yannick, Caillat-Zucman, Sophie, Flament, Caroline, Caignard, Anne, Messaoudene, Meriem, Aupérin, Anne, Vielh, Philippe, Dessen, Philippe, Porta, Camillo, Mateus, Christine, Ayyoub, Maha, Valmori, Danila, and Eggermont, Alexander
- Subjects
- *
CD4 antigen , *CD antigens , *VIRAL receptors , *MELANOMA treatment , *CANCER - Abstract
Beyond cancer-cell intrinsic factors, the immune status of the host has a prognostic impact on patients with cancer and influences the effects of conventional chemotherapies. Metastatic melanoma is intrinsically immunogenic, thereby facilitating the search for immune biomarkers of clinical responses to cytotoxic agents. Here, we show that a multi-tyrosine kinase inhibitor, sorafenib, upregulates interleukin (IL)-15Ra in vitro and in vivo in patients with melanoma, and in conjunction with natural killer (NK) group 2D (NKG2D) ligands, contributes to the Th1 polarization and accumulation of peripheral CD4+NKG2D+ T cells. Hence, the increase of blood CD4+NKG2D+ T cells after two cycles of sorafenib (combined with temozolomide) was associated with prolonged survival in a prospective phase I/II trial enrolling 63 patients with metastatic melanoma who did not receive vemurafenib nor immune checkpoint--blocking antibodies. In contrast, in metastatic melanoma patients treated with classical treatment modalities, this CD4+NKG2D+ subset failed to correlate with prognosis. These findings indicate that sorafenib may be used as an "adjuvant" molecule capable of inducing or restoring IL-15Rα/ IL-15 in tumors expressing MHCclass I--related chain A/B (MICA/B) and on circulating monocytes of responding patients, hereby contributing to the bioactivity of NKG2D+ Th1 cells. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
16. Mature Cytotoxic CD56bright/CD16+ Natural Killer Cells Can Infiltrate Lymph Nodes Adjacent to Metastatic Melanoma.
- Author
-
Messaoudene, Meriem, Fregni, Giulia, Fourmentraux-Neves, Emmanuelle, Chanal, Johan, Maubec, Eve, Mazouz-Dorval, Sarra, Couturaud, Benoit, Girod, Angelique, Sastre-Garau, Xavier, Albert, Sebastien, Guédon, Charles, Deschamps, Lydia, Mitilian, Delphine, Cremer, Isabelle, Jacquelot, Nicolas, Rusakiewicz, Sylvie, Zitvogel, Laurence, Avril, Marie-Francoise, and Caignard, Anne
- Subjects
- *
KILLER cells , *IMMUNOCOMPETENT cells , *LYMPH nodes , *LYMPHATICS , *MELANOMA - Abstract
Melanomas are characterized by high metastatic potential, with regional lymph node representing the most frequent site of early dissemination in this disease. These regional lymph nodes also represent the primary site for differentiation of natural killer (NK) cells. Although blood-derived NK cells can efficiently lyse melanoma cells isolated from metastatic lymph node (M-LN), there has been no study of the properties of the most disease-relevant NK cells isolated from M-LN in patients with melanoma. Here, we report that M-LN contains 0.5% to 11% of CD56bright NK cells among CD45+ hematopoietic cells present and that this cell population surrounds tumor cell clusters in M-LN. This NK cell population was characterized by expression of CD62L, chemokine receptors, and high levels of natural cytotoxicity receptors (NCR), NK group 2 D (NKG2D), and DNAX accessory molecule 1 (DNAM-1). Expression of NCR-NKp30 and NKG2D correlated negatively with percentages of tumor cells in M-LN. Interestingly, M-LN contained a unique subset of mature CD56bright CD16+ NK cells displaying coregulated expression of NCR and NKG2D activating receptors. Ex vivo analyses suggested that M-LN--derived NK cells were inactive but could be activated by appropriate cytokine signals [interleukin (IL)-2 or IL-15], and could lyse metastatic melanoma cells in a highly efficient manner compared with blood-derived NK cells. Taken together, the results offer evidence that adjuvant immunotherapy that targets NK cells in M-LN for activation may improve treatment of patients with sentinel lymph node--positive melanoma. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
17. TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves.
- Author
-
Enot, David P., Kroemer, Guido, Vacchelli, Erika, Zitvogel, Laurence, and Jacquelot, Nicolas
- Subjects
- *
TUMOR growth , *SURVIVAL - Abstract
The analysis of tumor growth curves is standard practice in experimental oncology including tumor immunology. In experimental oncology, cancer cells are inoculated into rodents (mostly mice) and their growth is monitored by measuring tumor diameter, surface or volume over time as a function of distinct treatments. Then, different groups of tumors/treatments are compared among each other for their evolution and possible responses to treatment. The R package TumGrowth has been created as a software tool allowing to carry out a series of statistical comparisons across or between groups of tumor growth curves obtained in a standard laboratory, for experimenters with limited knowledge in statistics. TumGrowth is freely available online at
https://kroemerlab.shinyapps.io/TumGrowth/ and can be downloaded into any computer. It offers an exhaustive panoply of tools to visualize and analyze complex data sets including longitudinal, cross-sectional and time-to-endpoint measurements. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
18. NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: Unique NKp30 pattern in rare melanoma patients with favorable evolution.
- Author
-
Messaoudene, Meriem, Fregni, Giulia, Enot, David, Jacquelot, Nicolas, Neves, Emmanuelle, Germaud, Nathalie, Garchon, Henri Jean, Boukouaci, Wahid, Tamouza, Ryad, Chanal, Johan, Avril, Marie-Françoise, Toubert, Antoine, Zitvogel, Laurence, Rusakiewicz, Sylvie, and Caignard, Anne
- Subjects
- *
NEUROENDOCRINE tumors , *MELANOMA , *PATIENTS - Abstract
Given the NK cell-based immunosurveillance of melanoma, we investigated the prognostic value of NKp46 transcript and NKp30 isoform (NKp30A, NKp30B and NKp30C) profiling in blood of 187 melanoma patients including 13 long survivors (LS), metastatic patients that have controlled the disease. Compared to healthy volunteers (HV), patients had reduced amounts of transcripts of the three NKp30 isoforms (NKp30 A, B and C) but similar ratios between NKp30 isoforms (ΔAB, ΔAC, ΔBC). Stratification of patients according to disease stage showed higher NKp30C and lower NKp46 transcripts in stage IV patients. Furthermore, patients with previous history of conventional chemotherapy displayed reduced NKp30A transcripts. The expression levels of NKp30 isoforms failed to predict survival from sampling of patients, while NKp46 expression predicted melanoma outcome. LS patients displayed elevated NKp30A levels, accordingly high ΔAB and ΔBC ratios, and a unique pattern of rare allelic variants of NKp30 SNPs. Moreover, NK cells from LS displayed correlated NKp30/NKp46 membrane expression, high spontaneous and NKp30- or NKp46-triggered degranulation. These data outline the impact of NKp30 and NKp46 transcripts on melanoma evolution and identify unique genetic features of NKp30 associated with higher NK activation in rare LS melanoma patients that control a metastatic disease. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.